NCT04940286 2026-04-16
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
53 trialsNCT05632328 2026-04-08
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT04233866 2026-03-23
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT04115163 2026-02-11
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT04241276 2026-01-07
STARPAC2
Queen Mary University of London
Phase 2 Active not recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT03910387 2025-12-16
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Emory University
Phase 2 Completed
NCT04858009 2025-12-16
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
Phase 2 Recruiting
NCT06177522 2025-11-18
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Jinling Hospital, China
Phase 2 Not yet recruiting
NCT02905578 2025-08-27
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
University of Iowa
Phase 2 Completed
NCT06423326 2025-07-30
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
NCT02723331 2025-07-01
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
University of Colorado, Denver
Phase 2 Completed
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04543071 2025-06-19
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT02340117 2025-05-30
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
SynerGene Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05827055 2025-05-23
ProGem
Georgetown University
Phase 2 Active not recruiting
NCT06390059 2025-04-30
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NovoCure Ltd.
Phase 2 Active not recruiting
NCT05841420 2025-01-29
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Aalborg University Hospital
Phase 2 Recruiting
NCT05562297 2025-01-22
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT05042128 2024-10-22
ASCEND
Australasian Gastro-Intestinal Trials Group
Phase 2 Active not recruiting
NCT06398587 2024-07-19
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04589234 2024-04-24
Saltikva for Metastatic Pancreatic Cancer
Salspera LLC
Phase 2 Active not recruiting
NCT04151277 2024-02-08
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
University of Glasgow
Phase 2 Unknown
NCT03415854 2023-12-15
NABPLAGEMD
HonorHealth Research Institute
Phase 2 Completed
NCT01470417 2023-08-22
GAIN-1
University of Florida
Phase 2 Completed
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT02080221 2022-08-01
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
Phase 2 Completed
NCT01461915 2022-06-06
PGPC1
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04089150 2021-10-22
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT04581876 2020-10-09
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT02289898 2020-09-28
YOSEMITE
Mereo BioPharma
Phase 2 Completed
NCT01839487 2020-07-20
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 2 Completed
NCT02106884 2019-11-06
QOLINPAC
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT02043730 2019-10-09
GAP
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 2 Completed
NCT02570711 2019-08-28
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Acerta Pharma BV
Phase 2 Terminated
NCT02124369 2019-07-16
PRICKLE
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01978184 2019-03-27
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
University of Pittsburgh
Phase 2 Completed
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT02023021 2019-02-05
Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Fudan University
Phase 2 Completed
NCT03825328 2019-01-31
A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )
Harbin Medical University
Phase 2 Unknown
NCT02109445 2019-01-10
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
Phase 2 Terminated
NCT02399137 2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2 Completed
NCT03636308 2018-08-17
ASAGPAC
Peking University
Phase 2 Unknown
NCT01921751 2018-07-13
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT01851174 2018-02-07
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Western Regional Medical Center
Phase 2 Terminated
NCT02017015 2017-09-26
PANC-001
Celgene
Phase 2 Completed
NCT00691054 2017-05-11
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
University of Miami
Phase 2 Completed